Jessie Lee Ann Alexander, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Alexander’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A113429 · Current
Licensed to practise in California · since 2023 · expires 2027-02-28 · Creighton University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$3,216 in 2024
Medicaid paid $3,216 for 17 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 17 | $3,216 |
| 2024 | 17 | 1 | 14 | $3,216 |
Money from drug and device companies
$46,490 in 2025
| 2025 | 1 | 37 | $41,723 | $46,490 |
| 2024 | 1 | 24 | $19,800 | $23,021 |
| 2023 | 1 | 3 | None | $240 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sobi | Gamifant | $46,490 | 37 payments
|
See all 37 published payments
| Sobi | Meals · 2025-12-22 | Gamifant | $92 |
| Sobi | Travel · 2025-12-22 | Gamifant | $253 |
| Sobi | Travel · 2025-12-22 | Gamifant | $342 |
| Sobi | Paid to speak or teach · 2025-12-22 | Gamifant | $4,140 |
| Sobi | Meals · 2025-12-22 | Gamifant | $145 |
| Sobi | Paid to speak or teach · 2025-12-22 | Gamifant | $5,733 |
| Sobi | Travel · 2025-12-22 | Gamifant | $62 |
| Sobi | Travel · 2025-12-22 | Gamifant | $687 |
| Sobi | Meals · 2025-12-22 | Gamifant | $94 |
| Sobi | Paid to speak or teach · 2025-10-22 | Gamifant | $4,141 |
| Sobi | Meals · 2025-10-17 | Gamifant | $117 |
| Sobi | Paid to speak or teach · 2025-10-17 | Gamifant | $3,822 |
| Sobi | Travel · 2025-10-17 | Gamifant | $17 |
| Sobi | Travel · 2025-09-26 | Gamifant | $272 |
| Sobi | Meals · 2025-09-26 | Gamifant | $121 |
| Sobi | Meals · 2025-09-26 | Gamifant | $65 |
| Sobi | Travel · 2025-09-26 | Gamifant | $248 |
| Sobi | Paid to speak or teach · 2025-09-26 | Gamifant | $5,733 |
| Sobi | Travel · 2025-09-26 | Gamifant | $273 |
| Sobi | Consulting · 2025-09-26 | Gamifant | $1,911 |
| Sobi | Meals · 2025-08-26 | Gamifant | $61 |
| Sobi | Meals · 2025-07-31 | Gamifant | $41 |
| Sobi | Paid to speak or teach · 2025-07-31 | Gamifant | $3,185 |
| Sobi | Meals · 2025-04-24 | Gamifant | $123 |
| Sobi | Meals · 2025-04-24 | Gamifant | $45 |
| Sobi | Paid to speak or teach · 2025-04-24 | Gamifant | $4,778 |
| Sobi | Travel · 2025-04-24 | Gamifant | $257 |
| Sobi | Paid to speak or teach · 2025-04-23 | None | $6,370 |
| Sobi | Meals · 2025-04-23 | None | $123 |
| Sobi | Travel · 2025-04-23 | None | $268 |
| Sobi | Travel · 2025-04-23 | None | $695 |
| Sobi | Travel · 2025-04-23 | None | $132 |
| Sobi | Meals · 2025-04-23 | None | $57 |
| Sobi | Consulting · 2025-03-28 | Gamifant | $1,911 |
| Sobi | Meals · 2025-02-13 | Gamifant | $131 |
| Sobi | Meals · 2025-02-13 | Gamifant | $21 |
| Sobi | Meals · 2025-02-13 | Gamifant | $23 |
See earlier years (2024, 2023)
2024: $23,021
| Sobi | Gamifant | $23,021 | 24 payments
|
2023: $240
| Sobi | Gamifant | $240 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Phase 2, Multicenter, Open-Label Study of Cc-97540 (Bms-986353), Cd19-Targeted Next Car T Cells, in Participants With Active Sle (Including Lupus Nephritis) With Inadequate Response To Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-Sle) · 2025 | Their institution | $24,710 |
| Merck Sharp & Dohme Corporation · A Phase 2b Open-Label, Single-Arm Trial To Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth To Less Than 18 Years of Age at-Risk of Developing Cmv Infection and,Or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation Hsct · 2021 | Their institution | $23,411 |
| Merck Sharp & Dohme LLC · A Phase 2b Open-Label, Single-Arm Trial To Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth To Less Than 18 Years of Age at-Risk of Developing Cmv Infection and,Or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation Hsct · 2022 | Their institution | $6,303 |
| Merck Sharp & Dohme LLC · A Phase 2b Open-Label, Single-Arm Trial To Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth To Less Than 18 Years of Age at-Risk of Developing Cmv Infection and,Or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation Hsct · 2023 | Their institution | $2,852 |
| Merck Sharp & Dohme Corporation · A Phase 2b Open-Label, Single-Arm Trial To Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth To Less Than 18 Years of Age at-Risk of Developing Cmv Infection and,Or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation Hsct · 2020 | Their institution | $2,756 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study To Evaluate the Efficacy and Safety of Adjunctive Karxt for the Treatment of Manic Episodes Or Mixed Manic Episodes in Individuals With Bipolar-I Disorder and Inadequate Response To Lithium, Valproate, Or Lamotrigine · 2025 | Their institution | $1,981 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2, Multicenter, Open-Label Study of Cc-97540 (Bms-986353), Cd19-Targeted Next Car T Cells, in Participants With Active Sle (Including Lupus Nephritis) With Inadequate Response To Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-Sle) · 2025 | Their institution | $825 |
Professional record
- NPI
- 1891922324
- Licence
- CA A113429, PA MD458861California A113429: Current · expires 2027-02-28
- Trained
- Creighton University School of Medicine, 2009
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2009-06-11
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.